Immunome, Inc. (IMNM)

Immunome, Inc. (IMNM) Healthcare & Pipeline Overview

Immunome, Inc. is a clinical-stage biopharmaceutical company specializing in antibody therapeutics for oncology and infectious diseases, including its lead candidate IMM-ONC-01 targeting IL-38 for tumor-derived immune evasion and IMM-BCP-01 for SARS-CoV-2, positioning it within a competitive biotechnology landscape focused on innovative therapeutic solutions.

What Is the Investment Thesis for IMNM?

Immunome, Inc. presents a compelling investment thesis based on its innovative antibody therapeutics platform targeting oncology and infectious diseases. The company's lead oncology program, IMM-ONC-01, targeting IL-38, offers a novel approach to cancer immunotherapy by blocking tumor-derived immune evasion. Clinical trials for IMM-ONC-01 could provide significant catalysts in the next 12-24 months. Furthermore, the development of IMM-BCP-01, an antibody cocktail for SARS-CoV-2, addresses an ongoing need for effective COVID-19 treatments. However, the company's negative profit margin of -3060.0% and gross margin of -630.3% highlight the financial risks associated with biotechnology companies in the clinical stage. Successful clinical outcomes and strategic partnerships are crucial for Immunome to achieve long-term value creation.

Based on FMP financials and quantitative analysis

IMNM Key Highlights

• Market Cap of $2.31B reflects investor confidence in Immunome's pipeline and technology platform.
• Negative Profit Margin of -3060.0% indicates the company is currently investing heavily in research and development.
• Gross Margin of -630.3% suggests high costs associated with early-stage drug development.
• Beta of 2.14 indicates higher volatility compared to the overall market.
• No Dividend reflects the company's focus on reinvesting earnings into growth initiatives.

Who Are IMNM's Competitors?

IMNM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMNM's Key Strengths?

• Innovative antibody discovery platform.
• Novel therapeutic targets in oncology and infectious diseases.
• Strong intellectual property portfolio.
• Experienced management team.

What Are IMNM's Weaknesses?

• Limited financial resources.
• Dependence on clinical trial outcomes.
• High attrition rate in drug development.
• Negative profit and gross margins.

What Could Drive IMNM Stock Higher?

• Clinical trial results for IMM-ONC-01 in oncology.
• Regulatory updates on IMM-BCP-01 for SARS-CoV-2 infections.
• Potential strategic partnerships and collaborations.
• Expansion of the therapeutic pipeline.

What Are the Key Risks for IMNM?

• Negative return on equity (-51.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and approval delays.
• Competition from established pharmaceutical companies.
• Limited financial resources.

What Are the Growth Opportunities for IMNM?

• Expansion of Oncology Pipeline: Immunome has the opportunity to expand its oncology pipeline beyond IMM-ONC-01 by identifying and validating additional novel therapeutic targets. The global oncology market is projected to reach $400 billion by 2030, providing a substantial market opportunity for innovative cancer therapies. Successful development and commercialization of new oncology assets could drive significant revenue growth for Immunome over the next 5-10 years.
• Advancement of IMM-BCP-01: Continued development and clinical validation of IMM-BCP-01 as a treatment for SARS-CoV-2 infections represents a significant growth opportunity. While the acute phase of the pandemic has subsided, the ongoing emergence of new variants and the need for effective treatments for immunocompromised individuals create a sustained market for COVID-19 therapeutics. Positive clinical data and regulatory approvals could lead to commercial partnerships and revenue generation within the next 2-3 years.
• Strategic Partnerships and Collaborations: Immunome can leverage strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapeutic candidates. Collaborations can provide access to funding, expertise, and resources, reducing the financial burden on Immunome and increasing the likelihood of successful product development. Securing partnerships for IMM-ONC-01 or IMM-BCP-01 could be a major catalyst for growth in the next 1-2 years.
• Application of Technology Platform to New Disease Areas: Immunome's antibody discovery platform can be applied to identify and develop therapeutics for a wide range of diseases beyond oncology and infectious diseases. Exploring new therapeutic areas, such as autoimmune disorders or neurodegenerative diseases, could diversify Immunome's pipeline and create new revenue streams. Initial research and development efforts in new disease areas could begin within the next 3-5 years.
• Out-Licensing and Commercialization: Immunome has the potential to out-license its therapeutic candidates to larger pharmaceutical companies for commercialization in specific geographic regions or indications. Out-licensing agreements can generate upfront payments, milestone payments, and royalties, providing a non-dilutive source of funding for Immunome's research and development activities. Securing out-licensing deals for IMM-ONC-01 or IMM-BCP-01 could provide significant financial benefits within the next 2-4 years.

What Opportunities Does IMNM Have?

• Expansion of pipeline into new disease areas.
• Strategic partnerships with larger pharmaceutical companies.
• Out-licensing of therapeutic candidates.
• Advancements in antibody engineering technologies.

What Threats Does IMNM Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and approval delays.
• Clinical trial failures.
• Changes in healthcare policies and reimbursement.

What Are IMNM's Competitive Advantages?

• Proprietary antibody discovery platform.
• Novel therapeutic targets, such as IL-38.
• Strong intellectual property portfolio.

What Does IMNM Do?

Immunome, Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biopharmaceutical company dedicated to discovering and developing innovative antibody therapeutics for the treatment of cancer and infectious diseases. The company's core technology platform focuses on identifying and validating novel therapeutic targets and developing corresponding antibody-based therapies. Immunome's lead oncology program, IMM-ONC-01, targets IL-38, a tumor-derived immune checkpoint that promotes evasion of the immune system. By blocking IL-38, IMM-ONC-01 aims to restore immune recognition and killing of cancer cells. In addition to its oncology pipeline, Immunome is also developing IMM-BCP-01, an antibody cocktail product candidate designed to neutralize SARS-CoV-2, the virus responsible for COVID-19. This cocktail approach aims to provide broad protection against different variants of the virus. Immunome's strategic focus on novel targets and antibody-based therapies positions it within the competitive biotechnology sector, striving to address unmet medical needs in oncology and infectious diseases.

What Products and Services Does IMNM Offer?

• Discovers and develops antibody therapeutics.
• Focuses on treatments for oncology and infectious diseases.
• Develops IMM-ONC-01, targeting IL-38 for cancer treatment.
• Develops IMM-BCP-01, an antibody cocktail for SARS-CoV-2 infections.
• Utilizes a proprietary technology platform for antibody discovery.
• Conducts preclinical and clinical studies to evaluate therapeutic candidates.

How Does IMNM Make Money?

• Develops antibody therapeutics for oncology and infectious diseases.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through upfront payments, milestone payments, and royalties from partnerships.

What Industry Does IMNM Operate In?

Immunome operates within the highly competitive biotechnology industry, characterized by rapid innovation, intense research and development, and stringent regulatory requirements. The market for antibody therapeutics is experiencing significant growth, driven by advancements in technology and increasing demand for targeted therapies in oncology and infectious diseases. Immunome's focus on novel targets and antibody-based therapies positions it to capitalize on these trends. However, the company faces competition from established pharmaceutical companies and other emerging biotechnology firms, including SYRE: Spyre Therapeutics, Inc., requiring continuous innovation and strategic execution to maintain a competitive edge.

Who Are IMNM's Key Customers?

• Patients suffering from cancer.
• Patients infected with SARS-CoV-2.
• Pharmaceutical companies seeking to in-license novel therapeutics.

FY2026 estForward Outlook

Wall Street analysts project Immunome, Inc. revenue of about $2.7M for fiscal 2026, with EPS near $-2.14. The estimate reflects 8 contributing analysts.

ROE -51%Key Financial Metrics

Return on equity for Immunome, Inc. stands at -51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Immunome, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 41.68 places it in the safe zone, indicating low near-term bankruptcy risk.

IMNM Valuation & Market Position

With a $2.31B market cap, Immunome, Inc. sits in the mid-cap segment of the market. Relative to its peer group, IMNM's quantitative score of 20/100 is below the peer average of 78/100.

IMNM Financials

IMNM Latest News

IMNM Analyst Consensus

IMNM MoonshotScore

Immunome, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources